Cancer News and Research

Latest Cancer News and Research

ESMO recognises 27 cancer centers for their excellent palliative care

The European Society for Medical Oncology is proud to announce that it has formally recognized 27 cancer centers for their commitment to providing excellent palliative care as part of the care they offer to patients.

23 Sep 2009

SEA technology to increase potency of monoclonal antibodies

Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.

23 Sep 2009

Drug trial for OSI-906 begins

TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

Breast cancer awareness campaign launched by Samsung Electronics Europe

Samsung Electronics Europe has launched ‘Everybody’s Doing It’, an online campaign and website which is a call to action encouraging women in Europe to check for breast cancer and prevent the disease from spreading. By visiting www.morethantalk.eu women can find an instant community of support, a place to make pledges to raise further awareness and a place to view or forward a short viral movie called ‘Everybody’s Doing It’; containing footage of eight women whose lives have been affected by breast cancer. The viral is intended to reach over 400,000 women - more than the number who are diagnosed with breast cancer in Europe every year.

23 Sep 2009

Results of IES presented at ECCO

Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.

23 Sep 2009

Celera and Medco collaborate in KIF6 gene variant testing

Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy. Current studies have suggested that only about 50 to 60 percent of the patients who receive a prescription for a lipid-lowering drug are taking the medication after six months.

23 Sep 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

Hyperthermia with chemotherapy prolongs survival

BSD Medical Corporation (NASDAQ:BSDM) reports that significant and “medical practice changing” clinical study results were the subject of a news briefing at Europe’s largest cancer congress, ECCO15 – ESMO34, which is being held September 20 to 24, 2009, in Berlin, Germany.

23 Sep 2009

NIH grants $3.4M to develop tools for identification of prostate cancer using MRI

Rutgers University and two collaborators have received a $3.4 million research grant to develop tools aimed at improving the identification of prostate cancer using MRI, or magnetic resonance imaging.

23 Sep 2009

Declining performance of muscles linked to harmful byproducts of air we breathe

If you think the air outside is polluted, a new research report in the September 2009 issue of the journal Genetics (http://www.genetics.org) might make you to think twice about the air inside our bodies too. That's because researchers show how about 3 percent of the air we breathe gets converted into harmful superoxides, which ultimately harm our muscles.

23 Sep 2009

Biotime's new subsidiary to focus on clinical development and marketing therapeutic stem cell products in China

BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China, and marketing stem cell research products in China and other countries in Asia.

23 Sep 2009

Decision Points helps patients with important medical decisions

Healthwise has released a new, interactive generation of its Decision Points to help people make better decisions with their doctors.

23 Sep 2009

CERE-110 trial to stop the progression of Alzheimer's disease

Researchers in the Memory Disorders Program at Georgetown University Medical Center are now recruiting volunteers for a national gene therapy trial - the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.

23 Sep 2009

McLaren Health Care and ProTom partner to bring Proton beam therapy to Michigan

Cancer patients residing in and near Michigan are one step closer to receiving one of the most advanced forms of treatment available with a new partnership being formed between McLaren Health Care and ProTom International, a Texas-based health care technology company.

23 Sep 2009

Patient recruitment completed for crucial glioblastoma study

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.

23 Sep 2009

FCI to educate women about fertility preservation

Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in fertility technologies now give patients the ability to preserve their fertility prior to treatment, an option many oncologists fail to inform their patients.

23 Sep 2009

Gamma Medica-Ideas closes $24 million financing to support digital technologies

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it had closed a $24 million financing, the company's first institutional round, in order to support continued growth of the company's proprietary digital SPECT, PET and CT technologies in current and new markets.

23 Sep 2009

Oncology Metrics and Altos Solutions to merge

Altos Solutions and Oncology Metrics llc, today announced the planned merger of the two companies, creating a combined technology and knowledge data company serving community-based oncology practices. The merged company will be known as Altos Solutions and will be headquartered in Los Altos, California.

23 Sep 2009

Obesity can increase cancer incidence in leukemic children

Obesity is an important factor contributing to chemotherapy resistance and increasing relapse rates among children with leukemia, according to recent findings published online first in Cancer Research, a journal of the American Association for Cancer Research.

23 Sep 2009